Synergistic interactions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro.

Article Details

Citation
Copy to clipboard

Chen P, Gearhart J, Protopopova M, Einck L, Nacy CA

Synergistic interactions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro.

J Antimicrob Chemother. 2006 Aug;58(2):332-7. Epub 2006 Jun 3.

PubMed ID
16751637 [ View in PubMed
]
Abstract

OBJECTIVES: The purpose of this study was to determine interactions of SQ109, a new asymmetric diamine tuberculosis (TB) drug candidate, with existing antitubercular drugs in vitro and assess its potential to improve combination drug activities against Mycobacterium tuberculosis. METHODS: Two-drug combinations at various concentrations below their MICs were tested for growth inhibition of M. tuberculosis using the BACTEC 460 system in vitro. Drug interactions were evaluated based on the quotient values that were derived numerically from the growth indices of cultures treated with a single antibiotic or combination treatment with two antibiotics. RESULTS: SQ109 at 0.5 of its MIC demonstrated strong Synergistic activity with 0.5 MIC isoniazid and as low as 0.1 MIC rifampicin in inhibition of M. tuberculosis growth. Additive effects were observed between SQ109 and streptomycin, but neither synergy nor additive effects were observed with the combination of SQ109 with ethambutol or pyrazinamide. The synergy between SQ109 and rifampicin was also demonstrated using rifampicin-resistant (RIFR) M. tuberculosis strains; SQ109 lowered the MIC of rifampicin for these drug-resistant strains. CONCLUSIONS: SQ109 interacts Synergistically with isoniazid and rifampicin, two of the most important front-line TB drugs. This finding supports efforts to further evaluate new combination therapies containing SQ109 in experimental animal models of TB that emulate future clinical trial studies in humans.

DrugBank Data that Cites this Article

Drugs